Mono-Hydroxy Sugammadex is an impurity of sugammadex, a cyclodextrin agent indicated for the treatment of neuromuscular blockade induced by rocuronium and vecuronium. It inactivates rocuronium by encapsulating (chelating) the free molecule to form a stable complex.
Mono-6-O-(p-toluenesulfonyl)-b-cyclodextrin, an indispensable compound in the biomedical sector, exhibits remarkable significance in augmenting the solubility, stability, and bioavailability of pharmaceuticals. Its vital function revolves around the formulation of diverse drugs, specifically those grappling with limited aqueous solubility. It finds extensive utilization within drug delivery systems, consequently fostering enhanced therapeutic effectiveness, thereby efficaciously combatting the targeted ailments.
Mono(6-ethanediamine-6-deoxy)-beta-cyclodextrin is a versatile compound widely used in the biomedical industry. It acts as a molecular carrier aiding in the solubilization and stabilization of various drugs, including anti-cancer agents, antibiotics, and antivirals. Additionally, it exhibits potential therapeutic efficacy against various diseases such as Alzheimer's, HIV/AIDS, and diabetes.
Mono(6-(1,6-hexamethylenediamine)-6-deoxy)-beta-cyclodextrin is a derivative of β-cyclodextrin, which can help improve the solubility of the drug in oral preparations or preparations.
Mometasone furoate, prodrug of the free form mometasone, is an agent with high affinity for the glucocorticoid receptor with anti-allergic property. It can be used to treat asthma and allergic rhinitis.
Mogroside IIIe is an exquisite natural compound hailing from Siraitia grosvenorii, revered for its antioxidant prowess. This divine extract aids in studying ailments of oxidative magnitude.
It can be used in biological study in influence of plant growth regulators on shoot proliferation and secondary metabolite production in micropropagated Huernia hystrix.
ML-SI3 is an antagonist of the TRPML family of calcium channels. ML-SI3 can prevent lysosomal calcium efflux and has been reported to block downstream TRPML1-mediated induction of autophagy.
MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity. TORC1/2 inhibitor INK128 binds to and inhibits both TORC1 and TORC2 complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.
ML-390 is an inhibitor of human DHODH, which induces differentiation in acute myeloid leukemia cell lines U937 (murine) and THP-1 (human) cell lines with an EC50 value of approximately 2 µM.
ML241 is a selective p97 ATPase inhibitor and IC50 value is 100 nM. It can inhibit degradation of a p97-dependent but not a p97-independent proteasome substrate in a dual-reporter cell line. ML241 may be a novel agent for the treatment of cancer.
ML204 is a novel and potential TRPC4 Channel inhibitor. ML204 inhibited TRPC4β-mediated intracellular Ca(2+) rise with an IC(50) value of 0.96 μm and exhibited 19-fold selectivity against muscarinic receptor-coupled TRPC6 channel activation.
ML SA1 is an activator of TRPML channels. It can induce TRPML-mediated Ca2+ release from lysosomes and reduce cholesterol accumulation in Niemann-Pick type C macrophages.
ML 385 is a novel and specific inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2; IC50 = 1.9 µM). ML 385 blocks NRF2 transcriptional activity, and enhances the efficacy of carboplatin as well as other chemotherapeutic drugs in lung cancer cells (NSCLC).
MKC-3946 is a potent inhibitor of inositol-requiring enzyme 1α (IRE1α). It inhibits XBP1 mRNA splicing and exhibits cytotoxicity against AML cells. MKC-3946 leads to modest growth inhibition in MM cells but has no effect on normal mononuclear cells in vitro.
MK-8722 is a potent pan-AMPK activator that improves glucose homeostasis but induces cardiac hypertrophy. AMPK has long been of interest as a target for the treatment of Type 2 Diabetes Mellitus.
Grazoprevir is a hepatitis C virus protease inhibitor developed for the treatment of hepatitis C. It suppresses NS3 and NS4A, which play a role in the virus splitting its polyprotein into the functional virus proteins. Grazoprevir is often used in combination with elbasvir or ribavirin.
MK-4827 tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. It has a great activity in cancer cells with mutant BRCA-1 and BRCA-2, >330-fold selective against PARP3, V-PARP and Tank1.
MK-4101 is a potent and selective SMO Inhibitor of the Hedgehog Pathway with anti-tumor activity. MK-4101 targets the Hh pathway in tumor cells, showing the maximum inhibitory effect on Gli1 MK-4101 also induced deregulation of cell cycle and block of DNA replication in tumors.
MK-2206 is a highly selective Akt inhibitor with IC50 of 8 nM, 12 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. It is undergoing a phase II clinical trial for the treatment of ovarian, fallopian tube, or primary peritoneal cancer where there are mutations in P13K or AKT or low levels of PTEN.
MK-1775, also known as AZD-1775, is a WEE1 inhibitor and a small-molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.
MK-0731 is a synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP.
Mizagliflozin is a sodium-glucose transporter inhibitor. It is expected to improve postprandial hyperglycemia by suppressing glucose absorption from the intestine. It blocks intestinal glucose absorption and reduces GIP secretion in rats and humans, which suggests SGLT1 glucose transport is critical for GIP release. It is used for the treatment of diabetes.
Mivebresib is a BET inhibitor with potential antineoplastic activity. It disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. Mivebresib is also a MYC and the TMPRSS2-ETS fusion proteins inhibitor. Mivebresib can inhibit cell growth in susceptible tumors.
Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. It is used in the treatment of certain types of cancer, mostly metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin's lymphoma.
This active molecular is an α2δ-1 ligand being developed for pain associated with diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia which related to related to drugs such as gabapentin and pregabalin. Mirogabalin binds to the α2δ calcium channels (1 and 2) and was estimated to be much more potent than pregabalin. In Nov 2015, a Japanese company named Daiichi Sankyo plans a phase III trial for Postherpetic neuralgia and Neuropathic pain (in patients with diabetic peripheral neuropathy and renal impairment) in Japan . In May 2016, Pharmacokinetics and adverse data from a phase I trial in volunteers presented at the 35th Annual Scientific Meeting of the American Pain Society .
